

Supplemental Table S1. Impact of Gout in the Incidence of ESRD Based on the Presence of CKD

Variable	ESRD events, <i>n</i>	Follow-up duration, PY	Incidence rate, /1,000 PY	Unadjusted HR (95% CI)	Multivariate adjusted HR (95% CI)	
					Model 1	Model 2
CKD ⁻ Gout ⁻ (<i>n</i> =759,374)	5,241	6,803,721	0.77	1 (ref.)	1 (ref.)	1 (ref.)
CKD ⁻ Gout ⁺ (<i>n</i> =21,685)	257	191,510	1.34	1.75 (1.54–1.98)	1.48 (1.31–1.68)	1.49 (1.32–1.69)
CKD ⁺ Gout ⁻ (<i>n</i> =81,225)	5,395	658,237	8.20	1 (ref.)	1 (ref.)	1 (ref.)
CKD ⁺ Gout ⁺ (<i>n</i> =5,498)	932	40,413	23.06	2.87 (2.68–3.07)	2.22 (2.07–2.38)	2.24 (2.09–2.40)
<i>P</i> for interaction				<0.001	<0.001	<0.001

Model 1 was adjusted for age, sex, body mass index, alcohol consumption, smoking, regular exercise, low 25% income, and the presence of hypertension and dyslipidemia; Model 2 was adjusted for the factors in model 1, along with fasting blood glucose, duration of diabetes, prescription number of oral hypoglycemic agents, and insulin users.

ESRD, end-stage renal disease; CKD, chronic kidney disease; PY, person-year; HR, hazard ratio; CI, confidence interval.